OncoMatch

OncoMatch/Clinical Trials/NCT07174583

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

Is NCT07174583 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including IDE849 and durvalumab for small-cell lung cancer.

Phase 1/2RecruitingIDEAYA BiosciencesNCT07174583Data as of May 2026

Treatment: IDE849 · durvalumab · IDE161 — This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Neuroendocrine Tumor

Tumor Agnostic

Biomarker criteria

Required: DLL3 expression (positive)

Disease stage

Required: Stage IV

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Max 3 prior lines
Min 1 prior line

Must have received: platinum-based chemotherapy

For SCLC, this includes platinum-based therapy

Must have received: anti-PD-1 therapy

programmed death-1/programmed death-ligand 1 inhibitors (except for subjects who refuse or are judged by the Investigator to be unsuitable for immunotherapy)

Cannot have received: DLL3 antibody-drug conjugate

prior treatment with DLL3 ADC

Cannot have received: topoisomerase I inhibitor

prior treatment with a topoisomerase I inhibitor including an ADC with a topoisomerase I inhibitor payload

Lab requirements

Blood counts

adequate bone marrow function

Kidney function

adequate organ function

Liver function

adequate organ function

Have adequate bone marrow and organ function.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Sarah Cannon Research Institute at HealthONE · Denver, Colorado
  • Mayo Clinic Hospital - Florida · Jacksonville, Florida
  • Sarah Cannon Research Institute at Florida Cancer Specialists · Orlando, Florida
  • Piedmont Physicians Medical Oncology - Atlanta · Atlanta, Georgia
  • The University of Chicago Medical Center - Duchossois Center for Advanced Medicine · Chicago, Illinois

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify